bobbysee, page-3

How long is a piece of string?



But certainly as more data comes through, as milestones are met, the chances simply go up.

The big pivot here is really the ability to be able to start selling without a P3....even if only in a few select regions/countries. That will be one heck of a trigger.

Then add in the data:

1) Safety Profile
2) Not X but 2X (Ert as well as Bone Marrow replacement cohorts being addressed with our Pentosan)
3) Younger stratum deriving a safety profile along with efficacy. (Brazil MPS VI)
4) Peer Review to endorse data

Keep the above going, present it well, get authority approval, a deal will come.

There is a large difference in the passage of time between P2 and having to do a P3....the sense of imminent sales will be potentially pivotal here.


DYOR
My views